Trial Profile
A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs BPX 201 (Primary) ; Rimiducid
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Sep 2017.
- 25 Mar 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.